Sheng Li

111 Dade Road
Guangzhou, 510120, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Erratum for: Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.

Erratum for: Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.

Journal: Radiology

Published: April 28, 2026

Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.

Contrast-Enhanced US Using Perfluorobutane for Diagnosing Small HCC in High-Risk Patients: Comparison with MRI LI-RADS Version 2018.

Journal: Radiology

Published: March 03, 2026

Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.

Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients.

Journal: Korean journal of radiology

Published: September 02, 2024

MRI findings of newly present benign focal hepatic observations following chemotherapy: distinct features in early- and late-term follow-up.

MRI findings of newly present benign focal hepatic observations following chemotherapy: distinct features in early- and late-term follow-up.

Journal: European radiology

Published: January 15, 2024

Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT.

Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT.

Journal: BMC infectious diseases

Published: August 31, 2023

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.

Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and the Risk of Cirrhosis in Patients with Chronic Hepatitis B-A Retrospective Cohort Study.

Journal: Diabetes, metabolic syndrome and obesity : targets and therapy

Published: April 07, 2022

Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.

Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.

Journal: Cancer management and research

Published: April 01, 2022

Differences in MicroRNA Expression in Chronic Hepatitis B Patients with Early Liver Fibrosis Based on Traditional Chinese Medicine Syndromes.

Differences in MicroRNA Expression in Chronic Hepatitis B Patients with Early Liver Fibrosis Based on Traditional Chinese Medicine Syndromes.

Journal: Evidence-based complementary and alternative medicine : eCAM

Published: May 28, 2020

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5.

Gene therapy for unresectable hepatocellular carcinoma using recombinant human adenovirus type 5.

Journal: Medical oncology (Northwood, London, England)

Published: May 20, 2014

Showing 1-9 of 9

Last Updated: 09/26/2026